Drug intelligence / Profile preview

autologous tSVFem

Development stage
Unknown
Modality
Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration
Intravenous, Intraarticular, Intramuscular, Intralesional, Intrathecal
01

Overview

Autologous tSVFem appears to refer to an autologous cell therapy product, where "autologous" indicates that the cells used are derived from the same individual who will receive the treatment. The abbreviation "tSVFem" is not recognized in standard medical or pharmaceutical literature, and no specific information about its mechanism of action, developer, or primary indication could be found in available sources. Generally, autologous cell therapies involve collecting a patient's own cells (such as stem cells), processing or modifying them outside the body, and then re-infusing them for therapeutic purposes. These therapies are commonly used in oncology (e.g., hematologic malignancies) and regenerative medicine[2][5][8]. Without further context on what "tSVFem" specifically denotes—whether it refers to a particular cell type, modification process, or disease target—the precise description cannot be determined.

Beyond the preview

Go deeper on autologous tSVFem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous tSVFem.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call